Reed John C - May 1, 2025 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, Innovative Medicine, R&D
Signature
/s/ Laura H. McFalls, as attorney-in-fact for John C. Reed
Stock symbol
JNJ
Transactions as of
May 1, 2025
Transactions value $
-$1,719,723
Form type
4
Date filed
5/5/2025, 05:10 PM
Previous filing
Feb 19, 2025
Next filing
Jul 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
REED JOHN C EVP, Innovative Medicine, R&D ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK /s/ Laura H. McFalls, as attorney-in-fact for John C. Reed 2025-05-05 0001181561

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $0 +25.3K +162.5% $0.00 40.8K May 1, 2025 Direct F1
transaction JNJ Common Stock Tax liability -$1.72M -11K -26.97% $156.31 29.8K May 1, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Restricted Share Units Options Exercise $0 -25.3K -50% $0.00 25.3K May 1, 2025 Common Stock 25.3K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting.
F2 Shares withheld for payment of taxes upon vesting of RSUs.